Covetrus Responds to FTC's Challenge on Merging with MWI Animal Health

Covetrus Responds to FTC's Merger Challenge



Covetrus, a prominent player in the animal health technology sector, has publicly addressed the recent actions taken by the Federal Trade Commission (FTC) regarding its proposed merger with MWI Animal Health, a subsidiary of Cencora. In a detailed statement released on November 13, 2026, the company expressed its stance on the merits of the merger and its anticipated benefits for veterinary practices.

The FTC has initiated a lawsuit aimed at challenging the merger, asserting that it could negatively impact competition within the veterinary market. However, Covetrus countered these claims by highlighting that the merger is poised to enhance the economic performance of veterinary clinics. The company emphasized that the FTC's understanding of the veterinary procurement landscape is outdated, failing to acknowledge the freely competitive options clinics currently enjoy.

According to Covetrus, veterinary clinics today have access to a variety of suppliers, allowing for flexible choice in sourcing animal health products. The integration of Covetrus and MWI is expected to streamline the procurement process, making it more efficient and reducing costs for these practices. The statement underscored the company's commitment to innovation, service reliability, and supporting a diverse supply chain that ultimately benefits veterinarians and their clients.

Covetrus provided data indicating that modern veterinary practices frequently switch between suppliers, reflecting a healthy level of competition fueled by the rise of online marketplaces. More than 60% of U.S. clinics reportedly utilize these platforms, granting them the ability to compare prices and streamline orders from numerous manufacturers and distributors. This competitive environment fosters price reductions—an outcome Covetrus asserts will persist regardless of the merger's progression.

In its defense, Covetrus highlighted that veterinary practices can purchase products from various channels, including direct sales from manufacturers, which operate independently of the distributors. With a robust sales strategy in place, manufacturers often have substantial contact with clinics, negating the FTC's concerns about monopolistic tendencies.

Moreover, the statement pointed out that the competitive landscape is further invigorated by retail entities that directly sell products like pharmaceuticals and pet food to consumers, thereby bypassing traditional distributors. This evolution in the market emphasizes the wide-reaching choices available to veterinary clinics, underlining their autonomy in making purchasing decisions.

Covetrus expressed confidence in the strategic benefits of the proposed merger and is prepared to robustly defend its position in court. The company is dedicated to improving financial and clinical outcomes for veterinary professionals, emphasizing its mission to support them through each stage of the veterinary care process.

In summary, as Covetrus navigates the regulatory landscape posed by the FTC, it continues to advocate for the merger with MWI Animal Health as a means to foster innovation and efficiency within the veterinary market. By enhancing both access to technology and quality of service, Covetrus aims to empower veterinarians to provide exceptional care for pets and their owners.

With this resolution looming, the industry watches closely to see how these developments might reshape the future of veterinary practice dynamics in the United States.

Topics Business Technology)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.